199 related articles for article (PubMed ID: 22652533)
1. A Finnish founder mutation in RAD51D: analysis in breast, ovarian, prostate, and colorectal cancer.
Pelttari LM; Kiiski J; Nurminen R; Kallioniemi A; Schleutker J; Gylfe A; Aaltonen LA; Leminen A; Heikkilä P; Blomqvist C; Bützow R; Aittomäki K; Nevanlinna H
J Med Genet; 2012 Jul; 49(7):429-32. PubMed ID: 22652533
[TBL] [Abstract][Full Text] [Related]
2. Recurrent moderate-risk mutations in Finnish breast and ovarian cancer patients.
Nurmi A; Muranen TA; Pelttari LM; Kiiski JI; Heikkinen T; Lehto S; Kallioniemi A; Schleutker J; Bützow R; Blomqvist C; Aittomäki K; Nevanlinna H
Int J Cancer; 2019 Nov; 145(10):2692-2700. PubMed ID: 30927251
[TBL] [Abstract][Full Text] [Related]
3. Analysis of RAD51D in ovarian cancer patients and families with a history of ovarian or breast cancer.
Thompson ER; Rowley SM; Sawyer S; kConfab ; Eccles DM; Trainer AH; Mitchell G; James PA; Campbell IG
PLoS One; 2013; 8(1):e54772. PubMed ID: 23372765
[TBL] [Abstract][Full Text] [Related]
4. Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals.
Kuusisto KM; Bebel A; Vihinen M; Schleutker J; Sallinen SL
Breast Cancer Res; 2011 Feb; 13(1):R20. PubMed ID: 21356067
[TBL] [Abstract][Full Text] [Related]
5. Screening of Finnish RAD51C founder mutations in prostate and colorectal cancer patients.
Pelttari LM; Nurminen R; Gylfe A; Aaltonen LA; Schleutker J; Nevanlinna H
BMC Cancer; 2012 Nov; 12():552. PubMed ID: 23176254
[TBL] [Abstract][Full Text] [Related]
6. Contribution of RAD51D germline mutations in breast and ovarian cancer in Greece.
Konstanta I; Fostira F; Apostolou P; Stratikos E; Kalfakakou D; Pampanos A; Kollia P; Papadimitriou C; Konstantopoulou I; Yannoukakos D
J Hum Genet; 2018 Nov; 63(11):1149-1158. PubMed ID: 30111881
[TBL] [Abstract][Full Text] [Related]
7. Founder BRCA1 and BRCA2 mutations in Ashkenazi Jews in Israel: frequency and differential penetrance in ovarian cancer and in breast-ovarian cancer families.
Levy-Lahad E; Catane R; Eisenberg S; Kaufman B; Hornreich G; Lishinsky E; Shohat M; Weber BL; Beller U; Lahad A; Halle D
Am J Hum Genet; 1997 May; 60(5):1059-67. PubMed ID: 9150153
[TBL] [Abstract][Full Text] [Related]
8. RAD51C is a susceptibility gene for ovarian cancer.
Pelttari LM; Heikkinen T; Thompson D; Kallioniemi A; Schleutker J; Holli K; Blomqvist C; Aittomäki K; Bützow R; Nevanlinna H
Hum Mol Genet; 2011 Aug; 20(16):3278-88. PubMed ID: 21616938
[TBL] [Abstract][Full Text] [Related]
9. Germline mutation in the RAD51B gene confers predisposition to breast cancer.
Golmard L; Caux-Moncoutier V; Davy G; Al Ageeli E; Poirot B; Tirapo C; Michaux D; Barbaroux C; d'Enghien CD; Nicolas A; Castéra L; Sastre-Garau X; Stern MH; Houdayer C; Stoppa-Lyonnet D
BMC Cancer; 2013 Oct; 13():484. PubMed ID: 24139550
[TBL] [Abstract][Full Text] [Related]
10. Screening of HELQ in breast and ovarian cancer families.
Pelttari LM; Kinnunen L; Kiiski JI; Khan S; Blomqvist C; Aittomäki K; Nevanlinna H
Fam Cancer; 2016 Jan; 15(1):19-23. PubMed ID: 26351136
[TBL] [Abstract][Full Text] [Related]
11. Germline mutations in RAD51D confer susceptibility to ovarian cancer.
Loveday C; Turnbull C; Ramsay E; Hughes D; Ruark E; Frankum JR; Bowden G; Kalmyrzaev B; Warren-Perry M; Snape K; Adlard JW; Barwell J; Berg J; Brady AF; Brewer C; Brice G; Chapman C; Cook J; Davidson R; Donaldson A; Douglas F; Greenhalgh L; Henderson A; Izatt L; Kumar A; Lalloo F; Miedzybrodzka Z; Morrison PJ; Paterson J; Porteous M; Rogers MT; Shanley S; Walker L; ; Eccles D; Evans DG; Renwick A; Seal S; Lord CJ; Ashworth A; Reis-Filho JS; Antoniou AC; Rahman N
Nat Genet; 2011 Aug; 43(9):879-882. PubMed ID: 21822267
[TBL] [Abstract][Full Text] [Related]
12. Loss of function germline mutations in RAD51D in women with ovarian carcinoma.
Wickramanayake A; Bernier G; Pennil C; Casadei S; Agnew KJ; Stray SM; Mandell J; Garcia RL; Walsh T; King MC; Swisher EM
Gynecol Oncol; 2012 Dec; 127(3):552-5. PubMed ID: 22986143
[TBL] [Abstract][Full Text] [Related]
13. About 1% of the breast and ovarian Spanish families testing negative for BRCA1 and BRCA2 are carriers of RAD51D pathogenic variants.
Gutiérrez-Enríquez S; Bonache S; de Garibay GR; Osorio A; Santamariña M; Ramón y Cajal T; Esteban-Cardeñosa E; Tenés A; Yanowsky K; Barroso A; Montalban G; Blanco A; Cornet M; Gadea N; Infante M; Caldés T; Díaz-Rubio E; Balmaña J; Lasa A; Vega A; Benítez J; de la Hoya M; Diez O
Int J Cancer; 2014 May; 134(9):2088-97. PubMed ID: 24130102
[TBL] [Abstract][Full Text] [Related]
14. High frequency and allele-specific differences of BRCA1 founder mutations in breast cancer and ovarian cancer patients from Belarus.
Bogdanova NV; Antonenkova NN; Rogov YI; Karstens JH; Hillemanns P; Dörk T
Clin Genet; 2010 Oct; 78(4):364-72. PubMed ID: 20569256
[TBL] [Abstract][Full Text] [Related]
15. The Norwegian founder mutations in BRCA1: high penetrance confirmed in an incident cancer series and differences observed in the risk of ovarian cancer.
Heimdal K; Maehle L; Apold J; Pedersen JC; Møller P
Eur J Cancer; 2003 Oct; 39(15):2205-13. PubMed ID: 14522380
[TBL] [Abstract][Full Text] [Related]
16. Comprehensive analysis of 989 patients with breast or ovarian cancer provides BRCA1 and BRCA2 mutation profiles and frequencies for the German population.
Meindl A;
Int J Cancer; 2002 Feb; 97(4):472-80. PubMed ID: 11802209
[TBL] [Abstract][Full Text] [Related]
17. Haplotype analysis suggest common founders in carriers of the recurrent BRCA2 mutation, 3398delAAAAG, in French Canadian hereditary breast and/ovarian cancer families.
Oros KK; Leblanc G; Arcand SL; Shen Z; Perret C; Mes-Masson AM; Foulkes WD; Ghadirian P; Provencher D; Tonin PN
BMC Med Genet; 2006 Mar; 7():23. PubMed ID: 16539696
[TBL] [Abstract][Full Text] [Related]
18. Mutation Analysis of the RAD51C and RAD51D Genes in High-Risk Ovarian Cancer Patients and Families from the Czech Republic.
Janatova M; Soukupova J; Stribrna J; Kleiblova P; Vocka M; Boudova P; Kleibl Z; Pohlreich P
PLoS One; 2015; 10(6):e0127711. PubMed ID: 26057125
[TBL] [Abstract][Full Text] [Related]
19. Ovarian and Breast Cancer Risks Associated With Pathogenic Variants in RAD51C and RAD51D.
Yang X; Song H; Leslie G; Engel C; Hahnen E; Auber B; Horváth J; Kast K; Niederacher D; Turnbull C; Houlston R; Hanson H; Loveday C; Dolinsky JS; LaDuca H; Ramus SJ; Menon U; Rosenthal AN; Jacobs I; Gayther SA; Dicks E; Nevanlinna H; Aittomäki K; Pelttari LM; Ehrencrona H; Borg Å; Kvist A; Rivera B; Hansen TVO; Djursby M; Lee A; Dennis J; Bowtell DD; Traficante N; Diez O; Balmaña J; Gruber SB; Chenevix-Trench G; Investigators K; Jensen A; Kjær SK; Høgdall E; Castéra L; Garber J; Janavicius R; Osorio A; Golmard L; Vega A; Couch FJ; Robson M; Gronwald J; Domchek SM; Culver JO; de la Hoya M; Easton DF; Foulkes WD; Tischkowitz M; Meindl A; Schmutzler RK; Pharoah PDP; Antoniou AC
J Natl Cancer Inst; 2020 Dec; 112(12):1242-1250. PubMed ID: 32107557
[TBL] [Abstract][Full Text] [Related]
20. BRCA1 testing in breast and/or ovarian cancer families from northeastern France identifies two common mutations with a founder effect.
Muller D; Bonaiti-Pellié C; Abecassis J; Stoppa-Lyonnet D; Fricker JP
Fam Cancer; 2004; 3(1):15-20. PubMed ID: 15131401
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]